{"id":"https://openalex.org/W2464815665","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9079","title":"Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).","display_name":"Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).","publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2464815665","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9079","mag":"2464815665"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.9079","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9079","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.9079","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046728958","display_name":"Martin Reck","orcid":"https://orcid.org/0000-0002-5348-4462","observed_orcids":["https://orcid.org/0000-0002-5348-4462"]},"institutions":[{"id":"https://openalex.org/I4210129183","display_name":"German Center for Lung Research","ror":"https://ror.org/03dx11k66","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4210129183","https://openalex.org/I4405256427"]},{"id":"https://openalex.org/I4210140903","display_name":"LungenClinic Grosshansdorf","ror":"https://ror.org/041wfjw90","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210140903"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Martin Reck","raw_affiliation_strings":["Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany;","institution_ids":["https://openalex.org/I4210129183","https://openalex.org/I4210140903"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052765751","display_name":"Luis G Paz-Ares","orcid":"https://orcid.org/0000-0002-1947-3364","observed_orcids":["https://orcid.org/0000-0002-1947-3364"]},"institutions":[{"id":"https://openalex.org/I4210153139","display_name":"Hospital Universitario Virgen del Roc\u00edo","ror":"https://ror.org/04vfhnm78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210153139"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Luis G. Paz-Ares","raw_affiliation_strings":["Virgen del Rocio University Hospital, Seville, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virgen del Rocio University Hospital, Seville, Spain;","institution_ids":["https://openalex.org/I4210153139"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089891961","display_name":"Paolo Bidoli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110840","display_name":"Azienda Ospedaliera San Gerardo","ror":"https://ror.org/01xf83457","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210110840"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paolo Bidoli","raw_affiliation_strings":["Ospedale S Gerardo, Monza, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ospedale S Gerardo, Monza, Italy;","institution_ids":["https://openalex.org/I4210110840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001928949","display_name":"Federico Cappuzzo","orcid":"https://orcid.org/0000-0002-6295-6767","observed_orcids":["https://orcid.org/0000-0002-6295-6767"]},"institutions":[{"id":"https://openalex.org/I4210149390","display_name":"Ospedale di Livorno","ror":"https://ror.org/04yrw5x43","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210149390"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Federico Cappuzzo","raw_affiliation_strings":["Istituto Toscano Tumori-Ospedale Civile Livorno, Livorno, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Istituto Toscano Tumori-Ospedale Civile Livorno, Livorno, Italy;","institution_ids":["https://openalex.org/I4210149390"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064449830","display_name":"Shaker R. Dakhil","orcid":"https://orcid.org/0000-0002-6261-5882","observed_orcids":["https://orcid.org/0000-0002-6261-5882"]},"institutions":[{"id":"https://openalex.org/I4210109973","display_name":"Cancer Center of Kansas","ror":"https://ror.org/0179s0197","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210109973"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shaker R. Dakhil","raw_affiliation_strings":["Cancer Center of Kansas, Wichita, KS;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Center of Kansas, Wichita, KS;","institution_ids":["https://openalex.org/I4210109973"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030455508","display_name":"Denis Moro\u2010Sibilot","orcid":"https://orcid.org/0000-0001-6776-8610","observed_orcids":["https://orcid.org/0000-0001-6776-8610"]},"institutions":[{"id":"https://openalex.org/I4210162920","display_name":"H\u00f4pital Albert Michallon","ror":"https://ror.org/05kfvx519","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2800555055","https://openalex.org/I4210162920"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Denis Moro-Sibilot","raw_affiliation_strings":["Thoracic Oncology Unit Teaching Hospital A Michallon, Grenoble, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thoracic Oncology Unit Teaching Hospital A Michallon, Grenoble, France;","institution_ids":["https://openalex.org/I4210162920"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012061864","display_name":"Hossein Borghaei","orcid":"https://orcid.org/0000-0002-2577-4454","observed_orcids":["https://orcid.org/0000-0002-2577-4454"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hossein Borghaei","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, PA;","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049294543","display_name":"Melissa Lynne Johnson","orcid":"https://orcid.org/0000-0001-9874-1314","observed_orcids":["https://orcid.org/0000-0001-9874-1314"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Lynne Johnson","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049504224","display_name":"Robert M. Jotte","orcid":"https://orcid.org/0000-0003-3920-0731","observed_orcids":["https://orcid.org/0000-0003-3920-0731"]},"institutions":[{"id":"https://openalex.org/I4210140702","display_name":"Rocky Mountain Cancer Centers","ror":"https://ror.org/03ynhs115","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert M. Jotte","raw_affiliation_strings":["Rocky Mountain Cancer Centers, Denver, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain Cancer Centers, Denver, CO;","institution_ids":["https://openalex.org/I4210140702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002170706","display_name":"Nathan A. Pennell","orcid":"https://orcid.org/0000-0002-1458-0064","observed_orcids":["https://orcid.org/0000-0002-1458-0064"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathan A. Pennell","raw_affiliation_strings":["Cleveland Clinic, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075347427","display_name":"Frances A. Shepherd","orcid":"https://orcid.org/0000-0002-3610-3533","observed_orcids":["https://orcid.org/0000-0002-3610-3533"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Frances A. Shepherd","raw_affiliation_strings":["Princess Margaret Cancer Centre, Toronto, ON, Canada;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Princess Margaret Cancer Centre, Toronto, ON, Canada;","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057281549","display_name":"Anne S. Tsao","orcid":"https://orcid.org/0000-0003-0505-6639","observed_orcids":["https://orcid.org/0000-0003-0505-6639"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne S. Tsao","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031548464","display_name":"Gebra Cuy\u00fan Carter","orcid":"https://orcid.org/0000-0002-6549-0069","observed_orcids":["https://orcid.org/0000-0002-6549-0069"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gebra Cuyun Carter","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031960674","display_name":"Faye Diehl","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Faye Diehl","raw_affiliation_strings":["Lilly Oncology, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Indianapolis, IN;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110533305","display_name":"Ekaterine Alexandris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ekaterine Alexandris","raw_affiliation_strings":["Eli Lilly and Company, Bridgewater, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Bridgewater, NJ;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007766452","display_name":"Pablo Lee","orcid":"https://orcid.org/0000-0002-3356-836X","observed_orcids":["https://orcid.org/0000-0002-3356-836X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pablo Lee","raw_affiliation_strings":["Eli Lilly and Company, Bridgewater, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Bridgewater, NJ;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113726350","display_name":"Annamaria Hayden Zimmermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Annamaria Zimmermann","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061100035","display_name":"Joseph Treat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Treat","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023811099","display_name":"Andreas I. Sashegyi","orcid":"https://orcid.org/0009-0009-9729-9320","observed_orcids":["https://orcid.org/0009-0009-9729-9320","https://orcid.org/0009-0002-2376-8824"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andreas Sashegyi","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043045128","display_name":"Maurice Pe\u0301rol","orcid":"https://orcid.org/0000-0002-3296-423X","observed_orcids":["https://orcid.org/0000-0002-3296-423X"]},"institutions":[{"id":"https://openalex.org/I4210105738","display_name":"Centre L\u00e9on B\u00e9rard","ror":"https://ror.org/01cmnjq37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210105738"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Maurice Perol","raw_affiliation_strings":["L\u00e9on-B\u00e9rard Cancer Centre, Lyon, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"L\u00e9on-B\u00e9rard Cancer Centre, Lyon, France;","institution_ids":["https://openalex.org/I4210105738"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"9079","last_page":"9079"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/stage-iv-non-small-cell-lung-cancer","display_name":"stage IV non-small cell lung cancer","score":0.8550000190734863},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9350000023841858},{"id":"https://openalex.org/keywords/ramucirumab","display_name":"ramucirumab","score":1.0},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.6710000038146973},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9200000166893005},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8949999809265137},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.968999981880188},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.6299999952316284},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6399999856948853},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.35899999737739563},{"id":"https://openalex.org/keywords/alk-rearrangement","display_name":"ALK rearrangement","score":0.6850000023841858},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.6869999766349792},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.6539999842643738},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.5950000286102295}],"concepts":[{"id":"https://openalex.org/C2779551604","wikidata":"https://www.wikidata.org/wiki/Q7290345","display_name":"Ramucirumab","level":3,"score":0.9537492394447327},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8966152667999268},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8605502843856812},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6807308197021484},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5639828443527222},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5239156484603882},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5061320662498474},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5052483677864075},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.486714631319046},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.47908884286880493},{"id":"https://openalex.org/C3018840467","wikidata":"https://www.wikidata.org/wiki/Q179661","display_name":"Second line treatment","level":3,"score":0.4425736963748932},{"id":"https://openalex.org/C3019258254","wikidata":"https://www.wikidata.org/wiki/Q1423317","display_name":"Second line","level":3,"score":0.413468599319458},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.36151158809661865},{"id":"https://openalex.org/C2993493390","wikidata":"https://www.wikidata.org/wiki/Q5453208","display_name":"First line","level":2,"score":0.28734850883483887},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.11373540759086609},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.9079","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9079","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.9079","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9789000153541565,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2767807598","https://openalex.org/W2744441485","https://openalex.org/W2613815573","https://openalex.org/W2589571680","https://openalex.org/W2901345254","https://openalex.org/W2561773736","https://openalex.org/W2140980839","https://openalex.org/W2559486449","https://openalex.org/W2596737360","https://openalex.org/W2309712002"],"abstract_inverted_index":{"9079":[0],"Background:":[1],"REVEL":[2,68],"demonstrated":[3],"that":[4,207],"the":[5,12,67,112,141,162,171,197],"addition":[6],"of":[7,15,31,40,53,75,106,165,170,182],"RAM":[8,98],"to":[9,21,35,55,92,128,191,305,334,342],"DOC":[10,94],"in":[11,25,61,66,135,215],"2L":[13],"treatment":[14,177,212],"pts":[16,54,63,134,148,156,186,205],"with":[17,72,80,187,196],"advanced":[18,73,188],"NSCLC":[19,74,189],"led":[20],"a":[22,44,50,107],"consistent":[23,195],"improvement":[24],"OS,":[26,283],"PFS,":[27,118,291],"and":[28,48,121],"ORR,":[29,119],"independent":[30],"histology.":[32],"Pts":[33,71],"refractory":[34,62,147,166,172,190,204],"1L":[36,86,192],"therapy":[37,193,263],"(best":[38],"response":[39],"progressive":[41],"disease)":[42],"have":[43],"particularly":[45],"poor":[46,163],"prognosis":[47,164],"represent":[49],"challenging":[51],"subgroup":[52,173],"treat.":[56],"We":[57],"report":[58],"relevant":[59],"outcomes":[60],"who":[64],"participated":[65],"trial.":[69],"Methods:":[70],"squamous":[76],"or":[77,84,101],"nonsquamous":[78],"histology":[79],"disease":[81],"progression":[82],"during":[83],"after":[85],"platinum-based":[87],"chemotherapy":[88],"were":[89,138,174],"randomized":[90],"(1:1)":[91],"receive":[93],"75":[95],"mg/m2and":[96],"either":[97],"10":[99],"mg/kg":[100],"PBO":[102],"on":[103],"day":[104],"1":[105,255],"21-day":[108],"cycle.":[109],"OS":[110,145],"was":[111,125,149],"primary":[113],"endpoint.":[114],"Secondary":[115],"endpoints":[116],"included":[117],"safety,":[120],"patient-reported":[122],"quality-of-life.":[123],"Response":[124],"assessed":[126],"according":[127],"RECIST":[129],"v1.1.":[130],"Results:":[131],"Of":[132],"1,253":[133],"REVEL,":[136],"29%":[137],"refractory.":[139],"In":[140],"control":[142],"arm,":[143],"median":[144,237],"among":[146],"6.3":[150,286],"mos":[151,154,265,284,292],"v":[152],"10.3":[153],"for":[155,184,203],"not":[157],"meeting":[158],"this":[159,216],"criterion,":[160],"demonstrating":[161],"pts.":[167],"Baseline":[168,232],"characteristics":[169],"balanced":[175],"between":[176],"arms.":[178],"Conclusions:":[179],"The":[180,200],"effect":[181],"RAM+DOC":[183,208,225],"treating":[185],"appears":[194],"intent-to-treat":[198],"population.":[199,218],"benefit/risk":[201],"profile":[202],"suggests":[206],"is":[209],"an":[210],"appropriate":[211],"option":[213],"even":[214],"difficult-to-treat":[217],"Clinical":[219],"trial":[220],"information:":[221],"NCT01168973.REVEL":[222],"Refractory":[223],"Pts.":[224],"n=178":[226],"PBO+DOC":[227],"n=182":[228],"HR":[229],"(95%":[230],"CI)":[231],"characteristics,":[233],"n":[234,311],"(%)":[235,312],"Age,":[236],"(range)":[238],"63":[239],"(23-84)":[240],"60":[241],"(29-87)":[242],"Male":[243],"137":[244],"(77)":[245],"127":[246],"(70)":[247,257,325],"ECOG":[248],"PS":[249],"0":[250],"53":[251],"(30)":[252],"50":[253,279],"(27)":[254,280],"125":[256],"132":[258],"(73)":[259,273],"Time":[260],"since":[261],"prior":[262],"<9":[264],"156":[266],"(88)":[267],"154":[268],"(85)":[269],"Histology":[270],"Nonsquamous":[271],"130":[272,274],"(71)":[275],"Squamous":[276],"46":[277],"(26)":[278],"Outcomes":[281],"Median":[282,290],"8.3":[285],"0.86":[287],"(0.68,":[288],"1.08)":[289],"4.0":[293],"2.5":[294],"0.71":[295],"(0.57,":[296],"0.88)":[297],"ORR":[298],"23%":[299],"13%":[300],"Total":[301],"LCSS":[302],"score,":[303],"time":[304],"deterioration":[306],"0.77":[307],"(0.51,":[308],"1.17)":[309],"TEAEs,":[310],"Any":[313],"TEAE":[314],"173":[315],"(97)":[316],"171":[317],"(95)":[318],"Gr":[319],"\u22653":[320],"TEAEs":[321,327,332,340],"131":[322],"(74)":[323],"126":[324],"Serious":[326],"80":[328],"(45)":[329],"84":[330],"(47)":[331],"leading":[333,341],"discontinuation":[335],"9":[336],"(5)":[337],"7":[338],"(4)":[339],"death":[343],"11":[344],"(6)":[345],"17":[346],"(9)":[347]},"counts_by_year":[{"year":2017,"cited_by_count":3}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-07-22T00:00:00"}